NAGENDRAN SUKUMAR sold 16.6% of their position (200K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $646.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/12/2025ACC: 0001415889-25-024369
Director
Since Sep 2020
-200K
Net shares
Net seller
$646.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
41.15K acquired · 241.15K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+41.15K
Price / share
$0.70
Trade value
$28.76K
% of position
3.5%
9/10/2025
1.17M→1.21M
Common Stock
Direct
Shares
−200K
Price / share
$3.23
Trade value
$646K
% of position
16.6%
9/10/2025
1.21M→1.01M
Total
Net shares
−158.85K
Net value
-$617.24K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/10/2025 | M · Option Exercise | +41.15K | $0.70 | $28.76K | 3.5% | 1.17M | 1.21M |
| Common Stock Direct | 9/10/2025 | S · Sale | −200K | $3.23 | $646K | 16.6% | 1.21M | 1.01M |
| Total | −158.85K | -$617.24K | ||||||
Derivative Transactions1
Employee Stock Option (right to buy)
Direct
Converts to
Common Stock
41.15K shares
Shares
−41.15K
Strike price
0.6989
Held after
292.86K
Exercisable
—
9/10/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) Direct | Common Stock41.15K shares | 9/10/2025 | M · Option Exercise | −41.15K | 0.6989 | — | 292.86K |